研究者業績

安岡 秀剛

ヤスオカ ヒデカタ  (Hidekata Yasuoka)

基本情報

所属
藤田医科大学 医学部 医学科 教授 (講座教授)
学位
博士(医学)(慶應義塾大学)

J-GLOBAL ID
200901028124352037
researchmap会員ID
1000315081

論文

 135
  • 田村 雄一, 伊波 巧, 小垣 滋豊, 重田 文子, 安岡 秀剛
    Pulmonary Hypertension Update 9(2) 80-87 2023年11月  
  • Hiroya Tamai, Kei Ikeda, Toshiaki Miyamoto, Hiroaki Taguchi, Chang-Fu Kuo, Kichul Shin, Shintaro Hirata, Yutaka Okano, Shinji Sato, Hidekata Yasuoka, Masataka Kuwana, Tomonori Ishii, Hideto Kameda, Toshihisa Kojima, Takehiro Taninaga, Masahiko Mori, Hideaki Miyagishi, Yasunori Sato, Wen-Chan Tsai, Tsutomu Takeuchi, Yuko Kaneko, Keisuke Izumi, Yasushi Kondo, Keiko Yoshimoto, Takahisa Gono, Sung-Hwan Park, Han Joo Baek, Yun Jong Lee, In Ah Choi, Jinhyun Kim, Ping-Ning Hsu, Chun-Ming Huan, Meng-Yu Weng, Wan-Yu Sung, Tien-Tsai Cheng
    The Lancet Rheumatology 5(4) e215-e224 2023年4月  
  • Tamai Hiroya, Ikeda Kei, Miyamoto Toshiaki, Taguchi Hiroaki, Hirata Shintaro, Okano Yutaka, Sato Shinji, Yasuoka Hidekata, Kuwana Masataka, Ishii Tomonori, Kameda Hideto, Kojima Toshihisa, Takeuchi Tsutomu, Kaneko Yuko
    日本リウマチ学会総会・学術集会プログラム・抄録集 67回 401-401 2023年3月  
  • 道祖田 直紀, 西野 譲, 伊藤 佑充, 松口 隆太, 澤田 茉莉加, 渡邉 奈津子, 長縄 達明, 梅田 愛, 赤松 このみ, 胡桃沢 芽久美, 橋本 貴子, 深谷 修作, 安岡 秀剛
    日本リウマチ学会総会・学術集会プログラム・抄録集 67回 900-900 2023年3月  
  • 橋本 貴子, 道祖田 直紀, 澤田 茉莉加, 伊藤 佑充, 渡邊 奈津子, 長縄 達明, 梅田 愛, 福井 潤, 赤松 このみ, 胡桃沢 芽久美, 平野 大介, 西野 譲, 深谷 修作, 安岡 秀剛
    中部リウマチ 52(1) 29-29 2023年3月  
  • 長縄 達明, 梅田 愛, 赤松 このみ, 胡桃沢 芽久美, 平野 大介, 橋本 貴子, 西野 譲, 深谷 修作, 安岡 秀剛
    日本内科学会雑誌 112(臨増) 161-161 2023年2月  
  • 長縄 達明, 星野 芽以子, 杉本 邦彦, 山田 晶, 加藤 靖周, 深谷 修作, 井澤 英夫, 安岡 秀剛
    日本肺高血圧・肺循環学会学術集会・日本小児肺循環研究会プログラム・抄録集 7回・28回 169-169 2022年7月  
  • Kotaro Matsumoto, Hidekata Yasuoka, Keiko Yoshimoto, Katsuya Suzuki, Tsutomu Takeuchi
    Scientific Reports 11(1) 2021年12月1日  
    Neutrophils form neutrophil extracellular traps (NETs), which are involved in the pathogenesis of ANCA-associated vasculitis (AAV). Recent reports suggest that platelets stimulated via toll-like receptor (TLR) pathways can induce NETs formation. However, the mechanism underlying the involvement of platelets in NETs formation in AAV is unknown. We investigated the role of platelets in the pathogenesis of AAV. Platelets from AAV patients and healthy controls (HCs) were co-cultured with peripheral neutrophils, and NETs formation was visualized and quantified. The expression levels of TLRs on platelets were examined by flow cytometry. Platelets were treated with a TLR agonist, platelet-derived humoral factor, CXCL4 (platelet factor 4: PF4), and/or anti-CXCL4 antibody to investigate the effects of TLR–CXCL4 signaling on NETs formation. Platelets from AAV significantly upregulated NETs formation in vitro. Flow cytometric analysis revealed that the proportion of TLR9 positive platelets was significantly higher in AAV than HCs. CXCL4 released from TLR9 agonist-stimulated platelets was significantly enhanced in AAV, which subsequently increased NETs formation. Further, neutralizing anti-CXCL4 antibody significantly inhibited NETs formation enhanced by platelets from AAV. TLR9 signaling and CXCL4 release underlie the key role that platelets play in NETs formation in the pathogenesis of AAV.
  • 長縄 達明, 赤松 このみ, 杉本 邦彦, 星野 芽衣子, 加藤 靖周, 山田 晶, 深谷 修作, 井澤 英夫, 安岡 秀剛
    日本肺高血圧・肺循環学会学術集会・日本小児肺循環研究会プログラム・抄録集 6回・27回 8-8 2021年5月  
  • 長縄 達明, 星野 芽衣子, 赤松 このみ, 杉本 邦彦, 山田 晶, 加藤 靖周, 深谷 修作, 井澤 英夫, 安岡 秀剛
    日本肺高血圧・肺循環学会学術集会・日本小児肺循環研究会プログラム・抄録集 6回・27回 48-48 2021年5月  
  • Mitsuhiro Akiyama, Katsuya Suzuki, Keiko Yoshimoto, Hidekata Yasuoka, Yuko Kaneko, Tsutomu Takeuchi
    Frontiers in Immunology 12 2021年4月14日  
    Objectives: Multiple studies suggest that interleukin (IL)-21 plays a pivotal role in the differentiation of B cells and activation of cytotoxic T cells and is involved in the pathogenesis of IgG4-related disease (IgG4-RD). T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is a new marker of T follicular helper (Tfh) cells, yet its significance remains unknown. The objective of this study was to investigate whether TIGIT expression could detect high IL-21-producing peripheral Tfh populations and their association with disease activity in IgG4-RD. Methods: TIGIT expression in peripheral CD4+T cell subsets was comprehensively analyzed by multi-color flow cytometry. Single cell mapping was performed by t-SNE method, and IL-21 production was compared in TIGIT+ and TIGIT-T cells. The effect of OX40 signal on cytokine expression was analyzed by RNA-sequencing. Clinical significance of TIGIT+ and TIGIT- peripheral T cells was analyzed in active patients with IgG4-RD, both at baseline and after 12 weeks of glucocorticoid treatment. Results: Unbiased single cell mapping revealed two high IL-21-producing peripheral T cell populations TIGIT+ Tfh and TIGIT-T helper cells. OX40 signal was associated with high IL-21 production in TIGIT+ Tfh and TIGIT-T helper cells. IL-21 production in Tfh cells correlated with the proportion of TIGIT+ cells in Tfh cells, serum IgG4 level, and scores of disease activity. Furthermore, the skewing toward peripheral TIGIT+ Tfh cells, particularly TIGIT+Tfh2 subset correlated with disease activity and was corrected by glucocorticoid treatment in IgG4-RD. Conclusions: OX40 is associated with high IL-21 production in peripheral TIGIT+ Tfh cells, and the increase in peripheral TIGIT+ Tfh cells reflects disease activity in IgG4-RD.
  • 長縄 達明, 西野 譲, 澤田 茉莉加, 渡邉 奈津子, 鈴木 雅司, 梅田 愛, 芦原 このみ, 胡桃沢 芽久美, 平野 大介, 橋本 貴子, 深谷 修作, 安岡 秀剛
    中部リウマチ 50(2) 18-18 2021年3月  
  • Okinori Murata, Katsuya Suzuki, Hiroaki Sugiura, Yasushi Kondo, Masaru Takeshita, Keiko Koga, Maiko Takiguchi, Rina Kurisu, Yoshiaki Kassai, Hidekata Yasuoka, Kunihiro Yamaoka, Rimpei Morita, Akihiko Yoshimura, Tsutomu Takeuchi
    Rheumatology (Oxford, England) 2021年2月16日  
    OBJECTIVES: We sought to clarify the presence of radiographic thymus variants using a scoring system, and their association with clinical and immunological features in RA patients. METHODS: 387 RA patients randomly selected from all patients visiting our department who underwent chest CT scanning, with exclusion of patients with thymoma or thymic cyst, or age < 30 y. Thymus size and attenuation score in axial CT images were quantitatively interpreted and assessed. Associations between immunophenotype data and clinical and serological features were analysed in a subset of patients. RESULTS: Thymic enlargement was found in 76 (19.6%) patients, and a thymus attenuation score ≥ 2 was found in 50 (12.9%) patients. The score was significantly associated with antibodies to citrullinated peptide antigens (ACPA) positivity. Thymic enlargement was significantly associated with the proportions of CD4+ effector memory T cells. CONCLUSION: Radiographic thymus variants were frequently observed in RA patients, and may reflect an abnormal immune response involved in the pathogenesis of RA.
  • Satoshi Takanashi, Jun Kikuchi, Takanori Sasaki, Mitsuhiro Akiyama, Hidekata Yasuoka, Keiko Yoshimoto, Noriyasu Seki, Kunio Sugahara, Kenji Chiba, Yuko Kaneko, Tsutomu Takeuchi
    Rheumatology (Oxford, England) 60(2) 967-975 2021年2月1日  
    OBJECTIVE: To clarify relevant proteins and clinical characteristics of a phenotype of IgG4-related disease (IgG4-RD) with lymphadenopathy. METHODS: We enrolled patients newly diagnosed with IgG4-RD in our department between January 2000 and June 2018 and performed proteomic analysis to measure serum concentrations of 1305 proteins. We extracted proteins overexpressed in patients with IgG4-RD with lymphadenopathy by comparing between those with lymphadenopathy, those without lymphadenopathy and healthy controls. We further reviewed all the patients with IgG4-RD in our institution and investigated the characteristics and prognosis of the patients with IgG4-RD with lymphadenopathy. RESULTS: Eighty-five patients with IgG4-RD were enrolled, of which, 55% had lymphadenopathy. Proteomic analysis in 31 patients with IgG4-RD and 6 healthy controls revealed that eotaxin-3 was a potential serum biomarker in the patients with lymphadenopathy versus those without lymphadenopathy and healthy controls. A cohort of 85 patients with IgG4-RD demonstrated that patients with lymphadenopathy showed a significantly higher serum IgG4, IgG4:IgG ratio, IgG4-RD responder index and eosinophilia (P < 0.001 for all), irrelevant of the extent to which organ involvement developed. Patients with lymphadenopathy treated with glucocorticoid alone relapsed with significantly higher rates than those without lymphadenopathy (P = 0.03). CONCLUSION: Lymphadenopathy in IgG4-RD represents a phenotype associated with high disease activities, eosinophilia and relapsing disease. Eotaxin-3 is a novel biomarker related to IgG4-RD with lymphadenopathy.
  • Tanaka Yoshiya, Kuwana Masataka, Fujii Takao, Kameda Hideto, Muro Yoshinao, Fujio Keishi, Itoh Yasuhiko, Yasuoka Hidekata, Fukaya Shusaku, Ashihara Konomi, Hirano Daisuke, Ohmura Koichiro, Tabuchi Yuya, Hasegawa Hisanori, Matsumiya Ryo, Shirai Yuichiro, Ogura Takehisa, Tsuchida Yumi, Ogawa-Momohara Mariko, Narazaki Hidehiko, Inoue Yoshino, Miyagawa Ippei, Nakano Kazuhisa, Hirata Shintaro, Mori Masaaki, the Japan research committee of the ministry of health,labor,and welfare for systemic autoimmune diseases
    Modern Rheumatology 31(1) 29-33 2021年1月  
  • Mari Ushikubo, Shuntaro Saito, Jun Kikuchi, Masaru Takeshita, Keiko Yoshimoto, Hidekata Yasuoka, Kunihiro Yamaoka, Noriyasu Seki, Katsuya Suzuki, Hisaji Oshima, Tsutomu Takeuchi
    Lupus 30(1) 61-69 2021年1月  
    BACKGROUND: Milk fat globule epidermal growth factor (MFG-E8) is related secreted protein which links phosphatidylserine on apoptotic cells and integrin αvβ3/5 on phagocytes. To clarify the clinical significance of MFG-E8 in SLE, we analyzed the correlation between expression level of MFG-E8 in circulating phagocytic leukocytes and clinical parameters of patients. METHODS: The study was conducted under a multi-center, prospective cohort design. Patients with one or both BILAG A or B, or SLEDAI- 2 K ≥ 4 with clinical symptoms were defined as the active SLE group. Expression of MFG-E8 on monocytes and concentration in serum were measured by FACS and ELISA, respectively. RESULTS: 96 subjects were enrolled. The absolute number and proportion of MFG-E8-positive monocytes to total monocytes were significantly higher in the active SLE group (p < 0.01). Importantly, the proportion was also significantly correlated with SLEDAI-2K, clinical SLEDAI, as well as serum levels of anti-ds-DNA antibody and complement and C1q. In addition, the proportion of MFG-E8-positive monocytes to total monocytes was significantly decreased from baseline in active SLE patients after 6 months' treatment and increased concordantly with disease activity in 6 refractory cases. Further, in receiver operating characteristic curve analysis for discrimination between active and inactive SLE, the AUC of the proportion of MFG-E8 was 0.854, which was equivalent to classical activity markers such as anti-ds DNA antibody (0.776), complement (0.897) and C1q (0.815). CONCLUSIONS: The proportion of MFG-E8-positive monocytes to total monocytes in peripheral blood was positively associated with disease activity in SLE and may be a novel biomarker of disease activity.
  • Komei Sakata, Hidekata Yasuoka, Keiko Yoshimoto, Tsutomu Takeuchi
    Rheumatology 59(12) 3961-3970 2020年12月1日  
    Abstract Objectives The regulation system for oxidative stress in systemic sclerosis (SSc) remains unclear. This study aimed to clarify the possible involvement of ataxia telangiectasia mutated (ATM), which plays a key role in DNA repair and redox balance, in the pathogenesis of SSc. Methods Thirty patients with SSc and 15 healthy controls were enrolled. Expression of ATM and phosphorylated ATM (pATM), an activated form of ATM, in phagocytes in whole blood samples was analysed by FACS. Correlations between expression levels of ATM/pATM and clinical parameters of SSc patients were statistically analysed. Peripheral monocytes were cultured with an ATM-specific inhibitor (KU55933), and reactive oxygen species production in the cells was measured. Results Expression level of pATM in peripheral monocytes and neutrophils from SSc patients was significantly lower than those in healthy controls (P = 0.04 and P &amp;lt; 0.001, respectively), while no significant difference in total ATM expression was observed between SSc and healthy controls. In addition, pATM expression in monocytes of SSc patients with interstitial lung disease or digital pitting scar was remarkably lower than in the patients without these clinical features (P = 0.02 and P = 0.03), respectively. Moreover, pATM expression in monocytes positively correlated with forced vital capacity and negatively correlated with the serum Krebs von den Lungen-6 level. Notably, KU55933, an ATM-specific inhibitor, enhanced reactive oxygen species production by monocytes under oxidative stress. Conclusion Our data revealed that decreased ATM activation in monocytes was associated with SSc-interstitial lung disease and that impaired ATM activation in monocytes may contribute to the disease process of SSc via uncontrolled reactive oxygen species production.
  • Yoshiki Kawamura, Takako Hashimoto, Hiroki Miura, Kei Kozawa, Akiko Yoshikawa, Naomi Ikeda, Hiroshi Yatsuya, Hidekata Yasuoka, Tetsushi Yoshikawa
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 132 104656-104656 2020年11月  
    BACKGROUND: Entire genome of human herpesvirus 6 (HHV-6) that integrates into human chromosomes is called chromosomally integrated HHV-6 (ciHHV-6). Several viral infections have been suggested to be involved in autoimmune connective tissue diseases (CTDs). Reactivated HHV-6 from the integrated viral genome can induce immune responses against the virus. Thus, it is plausible that ciHHV-6 is associated with autoimmune CTDs. OBJECTIVES: We sought to determine whether the prevalence of ciHHV-6 was significantly higher in patients with autoimmune CTDs than in a healthy population. STUDY DESIGN: A total of 846 peripheral blood samples collected from autoimmune CTD patients were analyzed. Since there was a large number of samples, they were pooled into 24 samples per group. Copy numbers of HHV-6 DNA were measured by real-time PCR. The threshold level for distinguishing between ciHHV-6 and active viral infection and the reliability of pooled DNA analysis were examined as initial validation experiments. RESULTS: The threshold level was 1.6 × 10^6 copy/mL in whole blood. The reliability of pooled DNA analysis to identify one ciHHV-6 sample among 23 HHV-6 DNA-negative samples was high. No HHV-6 DNA was detected in any of the pooled DNA samples collected from the patients. The probability of the present study including the 846 autoimmune CTD patient's samples was statistically not different with a healthy Japanese population which was 0.2 % or 0.6 %. CONCLUSIONS: There was no significant difference in the prevalence of ciHHV-6 between a healthy population and patients with autoimmune CTDs.
  • 橋本 貴子, 澤田 茉莉加, 渡邉 奈津子, 鈴木 雅司, 長縄 達明, 梅田 愛, 芦原 このみ, 胡桃沢 芽久美, 平野 大介, 西野 譲, 深谷 修作, 安岡 秀剛
    日本臨床免疫学会総会プログラム・抄録集 48回 112-112 2020年10月  
  • 梅田 愛, 澤田 茉莉加, 鈴木 雅司, 渡邉 奈津子, 長縄 達明, 芦原 このみ, 胡桃沢 芽久美, 平野 大介, 橋本 貴子, 西野 譲, 深谷 修作, 吉田 俊治, 安岡 秀剛
    日本リウマチ学会総会・学術集会プログラム・抄録集 64回 403-403 2020年8月  
  • 桑原 亜矢子, 平野 大介, 長縄 達明, 吉田 俊治, 安岡 秀剛
    日本リウマチ学会総会・学術集会プログラム・抄録集 64回 473-473 2020年8月  
  • 芦原 このみ, 澤田 茉莉加, 渡邉 奈津子, 鈴木 雅司, 長縄 達明, 梅田 愛, 胡桃沢 芽久美, 平野 大介, 橋本 貴子, 西野 譲, 深谷 修作, 吉田 俊治, 安岡 秀剛
    日本リウマチ学会総会・学術集会プログラム・抄録集 64回 509-509 2020年8月  
  • 胡桃沢 芽久美, 澤田 茉莉加, 渡邉 奈津子, 鈴木 雅司, 長縄 達明, 梅田 愛, 芦原 このみ, 平野 大介, 橋本 貴子, 西野 譲, 深谷 修作, 吉田 俊治, 安岡 秀剛, 杉浦 一充
    日本リウマチ学会総会・学術集会プログラム・抄録集 64回 580-580 2020年8月  
  • 長縄 達明, 吉田 俊治, 桑原 亜矢子, 澤田 茉莉加, 鈴木 雅司, 渡邉 奈津子, 梅田 愛, 芦原 このみ, 胡桃沢 芽久美, 平野 大介, 橋本 貴子, 西野 譲, 深谷 修作, 安岡 秀剛
    日本リウマチ学会総会・学術集会プログラム・抄録集 64回 594-594 2020年8月  
  • 平野 大介, 澤田 茉莉加, 渡邉 奈津子, 鈴木 雅司, 長縄 達明, 梅田 愛, 芦原 このみ, 胡桃沢 芽久美, 橋本 貴子, 西野 譲, 深谷 修作, 吉田 俊治, 安岡 秀剛
    日本リウマチ学会総会・学術集会プログラム・抄録集 64回 597-597 2020年8月  
  • 澤田 茉莉加, 芦原 このみ, 西野 譲, 渡邉 奈津子, 鈴木 雅司, 長縄 達明, 梅田 愛, 胡桃沢 芽久美, 平野 大介, 橋本 貴子, 深谷 修作, 吉田 俊治, 安岡 秀剛
    日本リウマチ学会総会・学術集会プログラム・抄録集 64回 618-618 2020年8月  
  • 鈴木 雅司, 深谷 修作, 澤田 茉莉加, 渡邉 奈津子, 長縄 達明, 梅田 愛, 芦原 このみ, 胡桃沢 芽久美, 平野 大介, 橋本 貴子, 西野 譲, 吉田 俊治, 安岡 秀剛
    日本リウマチ学会総会・学術集会プログラム・抄録集 64回 681-681 2020年8月  
  • 鈴木 雅司, 深谷 修作, 澤田 茉莉加, 渡邊 奈津子, 長縄 達明, 梅田 愛, 芦原 このみ, 平野 大介, 橋本 貴子, 西野 譲, 吉田 俊治, 安岡 秀剛
    中部リウマチ 49(2) 32-32 2020年3月  
  • 長縄 達明, 西野 譲, 深谷 修作, 吉田 俊治, 安岡 秀剛
    感染症学雑誌 94(臨増) 272-272 2020年3月  
  • Hiroshi Takei, Hidekata Yasuoka, Keiko Yoshimoto, Tsutomu Takeuchi
    Arthritis Research and Therapy 22(1) 2020年2月7日  
    Background: Interstitial lung disease (ILD) is a serious complication of connective tissue diseases (CTDs). Although immune dysregulation triggered by genetic and environmental factors is thought to provoke inflammation and subsequent fibrosis, precise mechanisms of these processes remain unclear. Recent reports suggest that activation of aryl hydrocarbon receptor (AhR) signals by various ligands such as tryptophan derivatives can induce hyper-immune responses and are involved in autoimmunity. We investigated the effects of AhR signals on the process of lung fibrosis and changes in immunological features using a bleomycin (BLM)-induced lung fibrosis mouse model. Methods: BLM was administered intratracheally to C57BL/6JJcl mice and either 5,11-dihydroindolo[3,2-b]carbazole-6-carboxaldehyde (FICZ), a natural AhR ligand, or vehicle was subsequently injected intraperitoneally on day 0, 1, and 2 from BLM administration. Mice were sacrificed at week 3, and lung fibrosis was quantified by the histological changes using the Ashcroft score and deposition of soluble collagen levels in the lung using Sircol assay. The population of immune cells infiltrated into the lungs was analyzed using flow cytometry. Results: Both the Ashcroft score and soluble collagen level in FICZ-treated mice were significantly lower than those in the vehicle group. Moreover, the survival rate of FICZ-treated mice was significantly higher than that of control mice during the 3 weeks after treatment. Interestingly, flow cytometric analysis revealed that the number of CD4+Foxp3+ regulatory T cells (Tregs) was significantly increased and CD4+IFNγ+ and γδ+IL-17A+ T cells were decreased in the lungs of FICZ-treated mice, while the total number of T, B, and NK cells were unaffected by FICZ treatment. Conclusions: Our findings suggest that stimulation of AhR signals attenuated lung fibrosis by increasing Tregs and suppressing inflammatory T cell subsets in a BLM-induced fibrosis model. AhR signaling pathways may therefore be useful therapeutic targets for connective tissue disease-associated ILD.
  • 梅田 愛, 長縄 達明, 芦原 このみ, 胡桃沢 芽久美, 平野 大介, 橋本 貴子, 西野 譲, 深谷 修作, 吉田 俊治, 安岡 秀剛
    日本内科学会雑誌 109(Suppl.) 223-223 2020年2月  
  • Yoshiya Tanaka, Masataka Kuwana, Takao Fujii, Hideto Kameda, Yoshinao Muro, Keishi Fujio, Yasuhiko Itoh, Hidekata Yasuoka, Shusaku Fukaya, Konomi Ashihara, Daisuke Hirano, Koichiro Ohmura, Yuya Tabuchi, Hisanori Hasegawa, Ryo Matsumiya, Yuichiro Shirai, Takehisa Ogura, Yumi Tsuchida, Mariko Ogawa-Momohara, Hidehiko Narazaki, Yoshino Inoue, Ippei Miyagawa, Kazuhisa Nakano, Shintaro Hirata, Masaaki Mori
    Modern rheumatology 1-5 2020年1月7日  査読有り
    Objective: To update and revise the diagnostic criteria for mixed connective tissue disease (MCTD) issued by the Japan Research Committee of the Ministry of Health, Labor, and Welfare (MHLW), a round table discussion by experts from rheumatology, dermatology, and pediatric medicine was conducted in multiple occasions.Methods: The definition of MCTD, and items included in the diagnostic criteria were generated by consensus method and evaluation using clinical data of typical and borderline cases of MCTD, by applying to the diagnostic criteria for MCTD proposed in 1996 and 2004 by the Research Committee of MHLW.Results: To the end, all committee members reached consensus. Then, the criteria were assessed in an independent validation cohort and tested against preexisting criteria. The revised criteria facilitate an understanding of the overall picture of this disease by describing the concept of MCTD, common manifestations, immunological manifestation and characteristic organ involvement. Conditions with characteristic organ involvement include pulmonary arterial hypertension, aseptic meningitis and trigeminal neuropathy. Even if the overlapping manifestations are absent, MCTD can be diagnosed based on the presence of the characteristic organ involvement. Furthermore, the criteria were validated for applicability in actual clinical cases, and public comments were solicited from the Japan College of Rheumatology and other associated societies.Conclusion: After being reviewed through public comments, the revised diagnostic criteria have been finalized.
  • Yoshiya Tanaka, Koji Oba, Takao Koike, Nobuyuki Miyasaka, Tsuneyo Mimori, Tsutomu Takeuchi, Shintaro Hirata, Eiichi Tanaka, Hidekata Yasuoka, Yuko Kaneko, Kosaku Murakami, Tomohiro Koga, Kazuhisa Nakano, Koichi Amano, Kazuyasu Ushio, Tatsuya Atsumi, Masayuki Inoo, Kazuhiro Hatta, Shinichi Mizuki, Shouhei Nagaoka, Shinichiro Tsunoda, Hiroaki Dobashi, Nao Horie, Norihiro Sato
    Annals of the rheumatic diseases 79(1) 94-102 2020年1月  査読有り
    OBJECTIVES: The aim of this study is to determine whether the 'programmed' infliximab (IFX) treatment strategy (for which the dose of IFX was adjusted based on the baseline serum tumour necrosis factor α (TNF-α)) is beneficial to induction of clinical remission after 54 weeks and sustained discontinuation of IFX for 1 year. METHODS: In this multicentre randomised trial, patients with IFX-naïve rheumatoid arthritis with inadequate response to methotrexate were randomised to two groups; patients in programmed treatment group received 3 mg/kg IFX until week 6 and after 14 weeks the dose of IFX was adjusted based on the baseline levels of serum TNF-α until week 54; patients in the standard treatment group received 3 mg/kg of IFX. Patients who achieved a simplified disease activity index (SDAI) ≤3.3 at week 54 discontinued IFX. The primary endpoint was the proportion of patients who sustained discontinuation of IFX at week 106. RESULTS: A total of 337 patients were randomised. At week 54, 39.4% (67/170) in the programmed group and 32.3% (54/167) in the standard group attained remission (SDAI ≤3.3). At week 106, the 1-year sustained discontinuation rate was not significantly different between two groups; the programmed group 23.5% (40/170) and the standard group 21.6% (36/167), respectively (2.2% difference, 95% CI -6.6% to 11.0%; p=0.631). Baseline SDAI <26.0 was a statistically significant predictor of the successfully sustained discontinuation of IFX at week 106. CONCLUSION: Programmed treatment strategy did not statistically increase the sustained remission rate after 1 year discontinuation of IFX treatment.
  • Jun Inamo, Jun Kikuchi, Katsuya Suzuki, Yuko Kaneko, Hidekata Yasuoka, Hirokazu Fujiwara, Kunihiro Yamaoka, Tsutomu Takeuchi
    Modern Rheumatology Case Reports 3(2) 119-123 2019年7月3日  
  • Kato M, Kaneko Y, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Nagasawa H, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Yokota I, Atsumi T, Takeuchi T
    Modern rheumatology 30(3) 1-8 2019年6月  査読有り
  • Sakata K, Kaneko Y, Yasuoka H, Takeuchi T
    Clinical rheumatology 39(1) 113-118 2019年6月  査読有り
  • Hidekata Yasuoka, Yuen Yu Angela Tam, Yuka Okazaki, Yuichi Tamura, Koichi Matsuo, Carol Feghali-Bostwick, Tsutomu Takeuchi, Masataka Kuwana
    Journal of Scleroderma and Related Disorders 4(2) 137-148 2019年5月19日  
    Objectives: To investigate the systemic sclerosis–related phenotype in fos-related antigen-1 transgenic mice and its underlying mechanisms. Methods: Lung and skin sections of constitutive fos-related antigen-1 transgenic mice and wild-type mice were examined by tissue staining and immunohistochemistry. The tricuspid regurgitation pressure gradient was measured by transthoracic echocardiography with a Doppler technique. To assess the impact of fos-related antigen-1 expression on macrophage function, bone marrow–derived mononuclear cells were derived from mice that expressed fos-related antigen-1 under the control of doxycycline and wild-type littermates. These bone marrow–derived mononuclear cells were induced to differentiate into macrophages with or without doxycycline, and analyzed for gene and protein expression. Finally, lung explants obtained from systemic sclerosis patients and control donors were subjected to immunohistochemistry. Results: The lungs of fos-related antigen-1 transgenic mice showed excessive fibrosis of the interstitium and thickening of vessel walls, with narrowing lumen, in an age-dependent manner. The tricuspid regurgitation pressure gradient was significantly elevated in fos-related antigen-1 transgenic versus control mice. Increased dermal thickness and the loss of subdermal adipose tissue were also observed in the fos-related antigen-1 transgenic mice. These changes were preceded by a perivascular infiltration of mononuclear cells, predominantly consisting of alternatively activated or M2 macrophages. Overexpressing fos-related antigen-1 in bone marrow–derived mononuclear cell cultures increased the expression of M2-related genes, such as Il10, Alox15, and Arg1. Finally, fos-related antigen-1-expressing M2 macrophages were increased in the lung tissues of systemic sclerosis patients. Conclusions: The fos-related antigen-1 transgenic mouse serves as a genetic model of systemic sclerosis that recapitulates the major vascular and fibrotic manifestations of the lungs and skin in systemic sclerosis patients. M2 polarization mediated by the up-regulation of fos-related antigen-1 may play a critical role in the development of systemic sclerosis.
  • Yasuoka H, Garrett SM, Nguyen XX, Artlett CM, Feghali-Bostwick CA
    American journal of physiology. Lung cellular and molecular physiology 316(4) L644-L655 2019年4月  査読有り
  • 田中 良哉, 小池 隆夫, 宮坂 信之, 三森 経世, 竹内 勤, 平田 信太郎, 田中 榮一, 安岡 秀剛, 金子 祐子, 村上 孝作, 古賀 智裕, 中野 和久, 天野 宏一, 牛尾 一康, 渥美 達也, 猪尾 昌之, 八田 和大, 水木 伸一, 長岡 章平, 角田 慎一郎, 土橋 浩章
    日本リウマチ学会総会・学術集会プログラム・抄録集 63回 472-472 2019年3月  
  • 長縄 達明, 桑原 亜矢子, 芦原 このみ, 平野 大介, 橋本 貴子, 西野 譲, 才藤 栄一, 深谷 修作, 吉田 俊治, 安岡 秀剛
    日本内科学会雑誌 108(臨増) 251-251 2019年2月  
  • Kondo Y, Suzuki K, Inoue Y, Sakata K, Takahashi C, Takeshita M, Kassai Y, Miyazaki T, Morita R, Niki Y, Kaneko Y, Yasuoka H, Yamaoka K, Yoshimura A, Takeuchi T
    Arthritis research & therapy 21(1) 14 2019年1月  査読有り
  • Yasuoka Hidekata, Sakata Komei, Yoshimoto Keiko, Takeuchi Tsutomu
    BLOOD 132 2018年11月29日  査読有り
  • Kaneko Y, Kato M, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Takeuchi T
    Annals of the Rheumatic Diseases 77(9) 1268-1275 2018年9月1日  査読有り
    © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. Objective To evaluate the sustained remission and low disease activity after discontinuation of tocilizumab in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate. Methods The SURPRISE study was a 2-year, open-label randomised controlled study. Among patients who had been randomised to additional tocilizumab (ADD-ON) or switch to tocilizumab (SWITCH) in the first year, those who achieved remission based on the disease activity score for 28 joints (DAS28-ESR&lt;2.6) discontinued tocilizumab at week 52 and were observed for the following 52 weeks. The endpoint of the second year included tocilizumab-free remission and low disease-activity rates, functional outcome, radiological outcomes assessed with the modified total Sharp score (mTSS) and safety. The efficacy of reinstituted tocilizumab/methotrexate was also evaluated. Results A total of 105 patients who achieved remission at week 52 discontinued tocilizumab; 51 in ADD-ON continued methotre
  • Tanaka Yoshiya, Oba Koji, Koike Takao, Miyasaka Nobuyuki, Mimori Tsuneyo, Takeuchi Tsutomu, Hirata Shintaro, Tanaka Eiichi, Yasuoka Hidekata, Kaneko Yuko, Murakami Kosaku, Koga Tomohiro, Nakano Kazuhisa, Amano Koichi, Ushio Kazuyasu, Atsumi Tatsuya, Inoo Masayuki, Hatta Kazuhiro, Mizuki Shinichi, Nagaoka Shohei, Tsunoda Shinichiro, Dobashi Hiroaki, Horie Nao, Sato Norihiro
    ARTHRITIS & RHEUMATOLOGY 70 2018年9月  査読有り
  • Tasaki S, Suzuki K, Kassai Y, Takeshita M, Murota A, Kondo Y, Ando T, Nakayama Y, Okuzono Y, Takiguchi M, Kurisu R, Miyazaki T, Yoshimoto K, Yasuoka H, Yamaoka K, Morita R, Yoshimura A, Toyoshiba H, Takeuchi T
    Nature communications 9(1) 2755 2018年7月  査読有り
  • Sakata K, Yasuoka H, Yoshimoto K, Yamaoka K, Takeuchi T
    ANNALS OF THE RHEUMATIC DISEASES 77 1281-1282 2018年6月  査読有り
  • Takei H, Yasuoka H, Yoshimoto K, Yamaoka K, Takeuchi T
    ANNALS OF THE RHEUMATIC DISEASES 77 738-738 2018年6月  査読有り
  • Yasuoka H, Sakata K, Yoshimoto K, Yamaoka K, Kuwana M, Takeuchi T
    ANNALS OF THE RHEUMATIC DISEASES 77 1281-1281 2018年6月  査読有り
  • Kaneko Y, Kato M, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Takeuchi T
    ANNALS OF THE RHEUMATIC DISEASES 77 105-106 2018年6月  査読有り

MISC

 195